title: No effect of pyridoxine on the incidence of myelosuppression during prolonged linezolid treatment.
abstract: Complications of long-term linezolid administration include anemia and thrombocytopenia. A recent report has suggested that pyridoxine may prevent myelosuppression. Pyridoxine was administered to 24 patients with bone infections who were being treated with linezolid. Thrombocytopenia occurred in 11 patients (45.8%), and anemia occurred in 6 (25%). We concluded that treatment wtih pyridoxine is unlikely to benefit patients who have been receiving linezolid for >2 weeks.
authors.affiliation: Fourth Department of Internal Medicine, Attiko University General Hospital, Haidari, Greece. dplach@med.uoa.gr
authors.forename: D
authors.initials: D
authors.lastname: Plachouras
authors.forename: E
authors.initials: E
authors.lastname: Giannitsioti
authors.forename: S
authors.initials: S
authors.lastname: Athanassia
authors.forename: F
authors.initials: F
authors.lastname: Kontopidou
authors.forename: A
authors.initials: A
authors.lastname: Papadopoulos
authors.forename: K
authors.initials: K
authors.lastname: Kanellakopoulou
authors.forename: H
authors.initials: H
authors.lastname: Giamarellou
mesh_terms: D000081:Acetamides / Q000009:adverse effects*; D000740:Anemia / Q000139:chemically induced / Q000188:drug therapy* / Q000453:epidemiology; D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D015994:Incidence; D000069349:Linezolid; D008297:Male; D008875:Middle Aged; D023303:Oxazolidinones / Q000009:adverse effects*; D011736:Pyridoxine / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000139:chemically induced / Q000188:drug therapy* / Q000453:epidemiology
chemical_list: D000081:Acetamides; D000900:Anti-Bacterial Agents; D023303:Oxazolidinones; D000069349:Linezolid; D011736:Pyridoxine